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Abstract 
 
Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of ovarian 
stimulation. It is feasible to identify patients at risk, modify stimulation strategies to 
ameliorate risk, and initiate out-patient treatments that alter disease pathophysiology to 
reduce disease severity. Mitigation of OHSS risk and severity, through innovative approaches 
prior to treatment, during treatment and after treatment should now be the standard care. This 
review summarizes recent developments and provides recommendations on the prevention 
and treatment of OHSS. 
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Introduction 
 
In vitro fertilisation (IVF) continues to transform lives around the world, with refinements in 
clinical and laboratory techniques driving an incessant improvement in outcomes. In 
particular, the adoption of pre-treatment biomarkers to individualise doses of exogenous 
gonadotrophins, use of gonadotrophin releasing hormone (GnRH) antagonists for prevention 
of premature luteinising hormone (LH) surges, the shift from using human chorionic 
gonadotrophin (hCG) to trigger final oocyte maturation prior to oocyte retrieval to use of 
GnRH agonists to induce an endogenous LH surge, and segmentation of the cycle by 
temporally separating the stimulation and embryo transfer by freezing all embryos, all have 
the potential to dramatically enhance the efficacy and safety of IVF.  
 
Unfortunately failure to comprehensively adopt these strategies, means that ovarian 
hyperstimulation syndrome (OHSS) is a potentially lethal iatrogenic complication of the early 
luteal phase and/or early pregnancy after ovarian stimulation [1-3]. OHSS has historically 
been classified on severity (mild, moderate, severe, critical) (Table 1) and by timing early 
(<9days) or late. Focus has however shifted to moderate or severe OHSS which affects 2-3% 
of patients, as milder forms may develop in 20-30% of all in-vitro fertilisation (IVF) cycles, 
and it is the moderate/severe OHSS which incurs risk of acute renal insufficiency, acute 
respiratory distress syndrome and venous thromboembolism [4]. Given the multiple 
classification systems available and potential for ascertainment bias, an objective 
reproducible pathway for OHSS classification has now been proposed for use in clinical trial 
reporting (Figure 1, Table 2), which complements existing clinical guidelines [1-4]. 
 
 
The pathophysiological changes of OHSS that underlie these events include arteriolar 
vasodilatation and increased capillary permeability. This facilitates a shift in fluid from the 
intra- to the extra-vascular compartment and the induction of a state of hypovolaemic 
hyponatremia with haemoconcentration. Although various systemic and local vasoactive 
mediators contribute to the pathogenesis of OHSS, vascular endothelial growth factor 
(VEGF) appears to be critical to the development of the condition [5]. VEGF is involved in 
corpus follicular growth, luteum function, angiogenesis, and vascular endothelial stimulation. 
In response to human chorionic gonadotrophin (hCG), VEGF mediates the vascular 
permeability of OHSS the cardinal feature of the syndrome [5]. It is this induction by hCG 
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that ensures OHSS is primarily self-limiting in those who are not pregnant but also why it 
may persist into the first trimester due to ongoing stimulation of the ovaries. Recognition of 
the critical contribution of hCG and VEGF to the pathogenesis of OHSS has facilitated 
successful treatment modification incorporating gonadotrophin antagonist control, agonist 
triggering and novel dopamine agonist preventative measures [1, 2].  The current review aims 
to summarise the latest evidence on the identification of patients at risk of OHSS, 
preventative measures and the treatment of OHSS. 
 
Who is at risk of moderate or severe OHSS? 
There are several pre-treatment characteristics such as young age, black race, ovulation 
disorder and polycystic ovarian syndrome (PCOS), which have been consistently associated 
with an increased risk of OHSS [6]. However, these are common risk factors and as such are 
not particularly useful in pre-treatment stratification of risk. In contrast biomarkers of the 
ovarian reserve and in particular an elevated anti-müllerian hormone (AMH)(>3.4ng/ml) or 
elevated antral follicle count (AFC)(>24), have been proven to be significantly more specific 
and sensitive and are now routinely recommended for the pre-treatment identification of 
patients at risk and for planning of ovarian stimulation cycles [1, 7]. Once patients have 
commenced treatment, additional characteristics related to the extent of multifollicular 
growth such as a visualisation of a ≥25 follicles, oestradiol on the day of trigger >3,500 pg/ml 
or ≥24 oocytes retrieved may aid in the prediction of patients who will develop OHSS [1]. 
 
How can we prevent OHSS? 
 
Use gonadotrophin-releasing hormone antagonists 
There are multiple trials demonstrating a reduction in OHSS by use of gonadotrophin-
releasing hormone (GnRH) antagonists for ovulation suppression as compared to GnRH 
agonist control [8]. The most recent Cochrane meta-analysis incorporating data from 20 
RCTs and 5141 patients suggested that use of GnRH antagonists was associated with a 
reduction in moderate and severe OHSS (OR 0.53 (95% CI 0.40, 0.69)) despite similar 
pregnancy and live-birth rates [8]. Notably many of the trials included in the meta-analysis 
were done in high-risk patients. However, recent confirmation of the efficacy of GnRH 
antagonists for a reduction in OHSS was obtained by an RCT of 1050 unselected women 
having their first treatment cycle (OR 0.43, 95% CI 0.33, 0.57) [9]. That live-birth rates were 
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similar for both treatment arms would suggest that a GnRH antagonist protocol would be the 
treatment of choice for the first IVF cycle in women <40years old [9]. 
 
Avoid aggressive ovarian stimulation 
Large scale population studies have demonstrated that cumulative live-birth rates plateau 
with oocyte yields ≥15, but that the risk of OHSS increases substantively beyond this point 
[10]. Despite this, clinicians frequently use large doses of gonadotrophins to try to attain large 
oocyte yields in excess of 15 oocytes, with the underlying belief that this will improve the 
overall chances of success. However, large oocyte yields have not been shown to be 
accompanied by an increase in good-quality blastocysts [11], and RCTs have shown a 
decrease  in fresh embryo transfer associated live-birth rates in women with high oocyte 
yields[12].  
 
Concomitant use of aspirin 
Aspirin inhibits platelet cyclooxygenase-1 (COX-1). A recent network meta-analysis 
suggested that aspirin (100mg/day) during ovarian stimulation, and continued until a negative 
pregnancy test or ultrasonographic evidence of embryonic cardiac activity may be a 
prophylactic regimen for OHSS (RR 0.07, 95% CI 0.07–0.30), with no detrimental side 
effects on clinical pregnancy rates [13]. It is noteworthy though that this beneficial effect was 
primarily driven by a large single centre study, with only two (0.25%) cases of severe or 
critical OHSS developing in the 780 high-risk patients treated with 100mg aspirin, as 
compared to 43 patients (8.4%) of the 412 who did not receive aspirin [14]. The only other 
smaller RCT (n=145) similarly reported a reduction in OHSS with aspirin [15]. To date there 
has not been widespread adoption of aspirin, with some, but not all recent guidelines 
supporting its use due to the limited evidence base [1, 2]. 
 
Concomitant use of metformin 
Metformin an oral biguanide, is recognised to reduce OHSS in a GnRH-agonist IVF cycles 
(OR 0.29; 95% CI 0.18 to 0.49) [16]. However, its role in GnRH antagonist cycles is less 
clear, with the most recent trial not demonstrating an impact of metformin on the incidence of 
moderate–severe OHSS [17], as compared to the only other older and smaller trial reported 
[18]. Furthermore that treatment with metformin during ovarian stimulation was still 
associated with an overall occurrence of moderate–severe OHSS of 14.1% in cycles triggered 
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with HCG, is no longer acceptable given that a substantive reduction in OHSS may be 
achieved by simply replacing hCG with a GnRH agonist trigger.  
 
Avoid exogenous and endogenous hCG exposure 
The structural similarity of hCG to luteinising hormone (LH), contributed to its adoption as 
the standard “trigger” for induction of final oocyte maturation [19]. In the stimulated ovary 
the longer half-life of hCG ensures sustained stimulation of LH receptors on the multiple 
corpus lutea, but as the luteinising granulosa cells of the corpus lutea are a major source of 
VEGF this also incurs a risk of OHSS. Reduction in the doses of hCG used to trigger oocyte 
maturation have had inconsistent effects on OHSS rates. Alternative strategies such as 
replacement of the hCG trigger with a GnRH agonist trigger to induce an endogenous LH 
surge in GnRH antagonist controlled cycles and/or elective cryopreservation of all embryos 
and thereby limiting endogenous hCG exposure, have been examined.  
 
Use of a GnRH agonist trigger alone is associated with a reduction in pregnancy rates in fresh 
transfers but not recipients of oocyte donors, suggesting that it compromises luteal function 
[20]. Although it is feasible to proceed to an embryo transfer after an agonist trigger by 
modifying the luteal support, this is still associated with a risk of OHSS irrespective of 
whether low dose hCG or purely exogenous steroid hormone support is provided [21, 22]. 
Consequently, the combination of an agonist trigger with elective cryopreservation of all 
embryos is now recognised as being highly effective at reducing the risk of OHSS [23]. 
Although initially toted as a means of achieving an OHSS free clinic [24], OHSS can still 
occur, albeit rarely. It should also be noted that patients who exhibit signs of significant 
suppression of the hypothalamic-pituitary axis, as determined by low serum LH (<0.5 
mIU/mL) on the day of trigger, have a 25% chance of a suboptimal response to use of a 
GnRH agonist for final oocyte maturation [25]. To overcome this inadequate response, dual 
triggering with hCG (1000IU) and GnRH agonist trigger have been used, but this negates the 
principal advantage of removing exogenous hCG, the principal driver of OHSS [26].  
 
Give a dopamine agonist after oocyte retrieval 
The dopamine-receptor agonist, cabergoline, partially inhibits the ovarian VEGF receptor 2 
(VEGFR-2) through a decrease in its phosphorylation levels; such inhibition, in turn, 
decreases the VEGFR-2–induced vascular permeability, without affecting luteal angiogenesis 
[5]. Several trials have now demonstrated that cabergoline administration (0.5mg/day) from 
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the day of hCG administration in high risk women can reduce the incidence and severity of 
early OHSS in GnRH agonist IVF cycles, while not compromising pregnancy rates [27]. 
Alternative dopamine agonists; quinagolide and bromocriptine, have also been associated 
with a reduction in OHSS, but they have been less extensively studied. 
 
Consider calcium gluconate infusion after oocyte retrieval 
Low intracellular calcium has a stimulatory role on adenylyl cyclase resulting in cAMP 
synthesis and thus renin release. By increasing circulating calcium concentrations by infusion 
of calcium gluconate, it was speculated that this would inhibit cAMP-stimulated renin 
release, decrease angiotensin II synthesis and VEGF production. Several studies including 
one double-blind RCT of 200 women have supported this theory, with administration of 
10mls of 10% calcium gluconate on the day of the oocyte retrieval and days 1, 2 and 3 after 
oocyte retrieval associated with a reduction on moderate and severe OHSS without 
compromising the pregnancy rate [13, 28]. 
 
Perform single embryo-transfer  
If proceeding to a fresh embryo transfer, transfer of a single embryo will reduce the risk of 
late onset OHSS. Circulating hCG concentrations reflect the number of pregnancies and are 
higher in multiple pregnancies [6].  
 
Additional adjuvant therapies and alternative strategies 
A wide range of alternative strategies including administration of luteal antagonist, letrozole, 
methyprednisolone, ketocanazole administration have been reported as being associated with 
a reduction in OHSS but the data on these treatments is limited [1, 2]. Witholding FSH for up 
to 4 days (coasting), has not been associated wth a reduced risk of OHSS in RCTs [1, 2]. 
Cancellation of the stimulation cycle and witholding hCG may prevent OHSS but strategies 
to prevent a spontaneous LH surge will be required.  
 
How can we treat OHSS? 
 
Once OHSS develops, traditional management involved rest and observation until the clinical 
picture deteriorates sufficiently to require hospitalization. It is now recognised that the 
described preventative strategies may be coupled with a protocol for the active management 
of patients during the luteal phase, when they first manisfest signs and symptoms of moderate 
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OHSS in an attempt to facilitate continued out-patient management [29]. For symptomatic 
women this entails critical fluid balance, with maintenance of oral fluid intake as guided by 
thirst to ensure intravascular perfusion and adequate diuresis, and commencement of 
prophylactic anticoagulation [1, 2]. Although there are no comparative studies addressing the 
value of thromboprophylaxis in women with severe OHSS, the use of prophylactic low 
molecular weight heparin (LMWH) prophylaxis is supported by the increased incidence of 
first trimester thrombosis in women with OHSS (16.8 VTE events per 1000 women, OR 99.7, 
95% CI 61.6–161.1) as compared to non-IVF pregnancies (0.2 VTE events per 1000 women) 
[30]. Thrombosis in women with OHSS frequently affects upper body sites, and clinicians 
should remain vigilant of patients presenting with unusual symptoms such as dizziness, loss 
of vision and neck pain [31]. With respect to duration of prophylaxis, the increased VTE risk 
may extend beyond the first trimester, and consequently thromboprophylaxis should be 
considered at least until the end of the first trimester, with further treatment decided in 
conjunction with a specialist haematologist[3]. 
 
For those with ascites, ultrasounded guided paracentesis/culdocentesis, may be performed in 
an out-patient setting, in the same way that an oocyte retrieval is performed. Drainage of 
ascites with relief of abdominal distension, infusion of colloid, and correction of deficient 
oral intake may allow rapid correction of the hemoconcentration, electrolyte abnormaliites 
and reduce the likelihood of progression. For some women, in-patient management will 
however be unavoidable as critical OHSS and severe OHSS with persistent 
haemoconcentration and dehydration will require multidisciplinary care and potentially 
intensive care.  
 
 
Conclusions 
Succesful mitigation of the risk of OHSS is now feasible. Biomarkers have enabled pre- 
treatment stratification of risk, with the use of GnRH antagonist protocols with a GnRH 
agonist trigger and elective cryopreservation of all embryos a particulary effective strategy. 
Other strategies including cabergoline and calcium gluconate are useful if proceeding to a 
fresh embryo transfer. In the absence of effective OHSS preventative strategies, fluid 
resuscitation, supportive care, paracentesis and prophylactic anticoagulation are 
recommended. 
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Figure 1: Ovarian hyperstimulation syndrome (OHSS) flow diagramfor use in the clinical trial setting. †Exaggerated response, as defined 
byWorld Health Organization criteria. ‡Subjects to be screened for OHSS symptoms on the day of embryo transfer, the day of positive 
pregnancy test or at the time of complaint. Shaded shapes denote required reporting of group in the context of a clinical trial. LFT, liver function 
test; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; Cr, creatinine. Adapted from [4]
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Category Features 
Mild OHSS Abdominal bloating 
 Mild abdominal pain 
 Ovarian size usually < 8 cm† 
  
Moderate OHSS Moderate abdominal pain 
 Nausea ± vomiting 
 Ultrasound evidence of ascites 
 Ovarian size usually 8–12 cm† 
  
Severe OHSS Clinical ascites (± hydrothorax) 
 Oliguria (< 300 ml/day or < 30 ml/hour) 
 Haematocrit > 0.45 
 Hyponatraemia (sodium < 135 mmol/l) 
 Hypo-osmolality (osmolality < 282 
mOsm/kg) 
 Hyperkalaemia (potassium > 5 mmol/l) 
 Hypoproteinaemia (serum albumin < 35 g/l) 
 Ovarian size usually > 12 cm† 
  
Critical OHSS Tense ascites/large hydrothorax 
 Haematocrit > 0.55 
 White cell count > 25,000/ml 
 Oliguria/anuria 
 Thromboembolism 
 Acute respiratory distress syndrome 
†
 Ovarian size may not correlate with severity of OHSS in cases of assisted reproduction because of the effect of follicular 
aspiration. Women demonstrating any feature of severe or critical OHSS should be classified in that category. 
 
Table 1:  RCOG classification of severity of OHSS.  
Adapted from [3]
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